Review



nlrp3 small molecule inhibitor compound 1  (Novartis)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Novartis nlrp3 small molecule inhibitor compound 1
    <t>NLRP3</t> pathway activation in mouse organotypic slice cultures. (A) IL-1β measurement in the supernatant of OSCs stimulated with lipopolysaccharides (LPS) and nigericin and treated with NLRP3 small molecule inhibitor (MCC950 or Compound 1). Elevated IL-1β levels in LPS + nigericin condition, which are significantly reduced by increasing concentration of NLRP3 inhibitors. Figure represents two independent experiments combined to increase the replicates per condition. Quantitative data are shown as individual datapoint, mean with standard error. PBS and LPS n = 16, Nigericin: n = 10, 10 nM, Compound 1: 100 nM ( n = 3), 300 nM ( n = 3), 10 μM ( n = 4); MCC950: 10 nM ( n = 3), 300 nM ( n = 4), 10 μM ( n = 2). (B) OSCs supernatant shows elevated IL-1β levels after K18 seeding, which are significantly decreased by addition of 1 μM NLRP3 small molecule inhibitor called JNJ81977038. Data are shown as individual datapoint, mean with standard error. Significance **** p < 0.0001 by one-way ANOVA with multiple comparisons test.
    Nlrp3 Small Molecule Inhibitor Compound 1, supplied by Novartis, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nlrp3+small+molecule+inhibitor/pmc11458539-140-8-18?v=Novartis
    Average 90 stars, based on 1 article reviews
    nlrp3 small molecule inhibitor compound 1 - by Bioz Stars, 2026-08
    90/100 stars

    Images

    1) Product Images from "NLRP3 inflammasome activation and pyroptosis are dispensable for tau pathology"

    Article Title: NLRP3 inflammasome activation and pyroptosis are dispensable for tau pathology

    Journal: Frontiers in Aging Neuroscience

    doi: 10.3389/fnagi.2024.1459134

    NLRP3 pathway activation in mouse organotypic slice cultures. (A) IL-1β measurement in the supernatant of OSCs stimulated with lipopolysaccharides (LPS) and nigericin and treated with NLRP3 small molecule inhibitor (MCC950 or Compound 1). Elevated IL-1β levels in LPS + nigericin condition, which are significantly reduced by increasing concentration of NLRP3 inhibitors. Figure represents two independent experiments combined to increase the replicates per condition. Quantitative data are shown as individual datapoint, mean with standard error. PBS and LPS n = 16, Nigericin: n = 10, 10 nM, Compound 1: 100 nM ( n = 3), 300 nM ( n = 3), 10 μM ( n = 4); MCC950: 10 nM ( n = 3), 300 nM ( n = 4), 10 μM ( n = 2). (B) OSCs supernatant shows elevated IL-1β levels after K18 seeding, which are significantly decreased by addition of 1 μM NLRP3 small molecule inhibitor called JNJ81977038. Data are shown as individual datapoint, mean with standard error. Significance **** p < 0.0001 by one-way ANOVA with multiple comparisons test.
    Figure Legend Snippet: NLRP3 pathway activation in mouse organotypic slice cultures. (A) IL-1β measurement in the supernatant of OSCs stimulated with lipopolysaccharides (LPS) and nigericin and treated with NLRP3 small molecule inhibitor (MCC950 or Compound 1). Elevated IL-1β levels in LPS + nigericin condition, which are significantly reduced by increasing concentration of NLRP3 inhibitors. Figure represents two independent experiments combined to increase the replicates per condition. Quantitative data are shown as individual datapoint, mean with standard error. PBS and LPS n = 16, Nigericin: n = 10, 10 nM, Compound 1: 100 nM ( n = 3), 300 nM ( n = 3), 10 μM ( n = 4); MCC950: 10 nM ( n = 3), 300 nM ( n = 4), 10 μM ( n = 2). (B) OSCs supernatant shows elevated IL-1β levels after K18 seeding, which are significantly decreased by addition of 1 μM NLRP3 small molecule inhibitor called JNJ81977038. Data are shown as individual datapoint, mean with standard error. Significance **** p < 0.0001 by one-way ANOVA with multiple comparisons test.

    Techniques Used: Activation Assay, Concentration Assay

    No effect of Nlrp3 knockout on tau pathology by IHC. (A) AT100 immunohistochemistry demonstrated no significant effect on tau phosphorylation/aggregation in all analyzed regions of late-stage Nlrp3 −/− xP301S vs. Nlrp3 +/+ xP301S mice. Brain stem, spinal cord, and midbrain showed a trend in reduced pathology for Nlrp3 deficiency, which was not significant. Early stage P301S mice displayed much lower aggregated tau levels compared to late-stage animals and no effect of Nlrp3 deletion on tauopathy was observed at this age in any of the regions analyzed. Image analysis data are shown as mean + individual values for each animal (average of two sections/animal). Early stage Nlrp3 +/+ xP301S: n = 24, Nlrp3 −/− xP301S: n = 26; Late-stage Nlrp3 +/+ xP301S: n = 18, Nlrp3 −/− xP301S: n = 19. No significance by unpaired t -test of age-matched groups. (B) Representative images of the AT00 IHC staining are demonstrated. Scale bars: 2.5 mm (overview images), 100 μm (higher magnification images). (C) Biochemical analysis of tau pathology in brainstem of Nlrp3 xP301S mice. Aggregated tau levels were not significantly reduced in the sarcosyl-insoluble fraction or total homogenate of the brainstem of late-stage Nlrp3 −/− vs. Nlrp3 +/+ xP301S mice. Early stage Nlrp3 +/+ xP301S: n = 23, Nlrp3 −/− xP301S: n = 25; Late-stage Nlrp3 +/+ xP301S: n = 16, Nlrp3 −/− xP301S: n = 16. Data are expressed as mean + individual values of each animal tested (values = average of two sections/mouse).
    Figure Legend Snippet: No effect of Nlrp3 knockout on tau pathology by IHC. (A) AT100 immunohistochemistry demonstrated no significant effect on tau phosphorylation/aggregation in all analyzed regions of late-stage Nlrp3 −/− xP301S vs. Nlrp3 +/+ xP301S mice. Brain stem, spinal cord, and midbrain showed a trend in reduced pathology for Nlrp3 deficiency, which was not significant. Early stage P301S mice displayed much lower aggregated tau levels compared to late-stage animals and no effect of Nlrp3 deletion on tauopathy was observed at this age in any of the regions analyzed. Image analysis data are shown as mean + individual values for each animal (average of two sections/animal). Early stage Nlrp3 +/+ xP301S: n = 24, Nlrp3 −/− xP301S: n = 26; Late-stage Nlrp3 +/+ xP301S: n = 18, Nlrp3 −/− xP301S: n = 19. No significance by unpaired t -test of age-matched groups. (B) Representative images of the AT00 IHC staining are demonstrated. Scale bars: 2.5 mm (overview images), 100 μm (higher magnification images). (C) Biochemical analysis of tau pathology in brainstem of Nlrp3 xP301S mice. Aggregated tau levels were not significantly reduced in the sarcosyl-insoluble fraction or total homogenate of the brainstem of late-stage Nlrp3 −/− vs. Nlrp3 +/+ xP301S mice. Early stage Nlrp3 +/+ xP301S: n = 23, Nlrp3 −/− xP301S: n = 25; Late-stage Nlrp3 +/+ xP301S: n = 16, Nlrp3 −/− xP301S: n = 16. Data are expressed as mean + individual values of each animal tested (values = average of two sections/mouse).

    Techniques Used: Knock-Out, Immunohistochemistry, Phospho-proteomics

    AT100 immunohistochemistry was not altered in Gsdmd deficient mice. (A) Immunohistochemistry with phospho-tau AT100 antibody showed no significant effect on tau pathology in Gsdmd xP301S mice. No significant difference is detected between Nlrp3 −/− xP301S vs. Nlrp3 +/+ xP301S mice at early and late stage. Quantitative data are shown as mean + individual values for each animal. Early stage Nlrp3 +/+ xP301S: n = ±10, Nlrp3 −/− xP301S: n = ±15; Late-stage Nlrp3 +/+ xP301S: n = ±25, Nlrp3 −/− xP301S: n = ±20. No significance by unpaired t -test of age-matched groups. (B) Representative images of brain stem, midbrain, spinal cord, and cortex are shown. The whole brain sections are displayed at 2.5 mm and the spinal cord sections are displayed at 100 μm.
    Figure Legend Snippet: AT100 immunohistochemistry was not altered in Gsdmd deficient mice. (A) Immunohistochemistry with phospho-tau AT100 antibody showed no significant effect on tau pathology in Gsdmd xP301S mice. No significant difference is detected between Nlrp3 −/− xP301S vs. Nlrp3 +/+ xP301S mice at early and late stage. Quantitative data are shown as mean + individual values for each animal. Early stage Nlrp3 +/+ xP301S: n = ±10, Nlrp3 −/− xP301S: n = ±15; Late-stage Nlrp3 +/+ xP301S: n = ±25, Nlrp3 −/− xP301S: n = ±20. No significance by unpaired t -test of age-matched groups. (B) Representative images of brain stem, midbrain, spinal cord, and cortex are shown. The whole brain sections are displayed at 2.5 mm and the spinal cord sections are displayed at 100 μm.

    Techniques Used: Immunohistochemistry

    Late-stage Nlrp3 effect on neurofilament levels and no effect of Gsdmd in P301S mice. (A) Neurofilament light (NF-L) levels were quantified in plasma of Nlrp3 xP301S mice as a surrogate marker for neurodegeneration in the CNS. At late stage, NF-L levels were significantly reduced in Nlrp3 knockout mice, compared to age-related Nlrp3 WT mice. No effect was demonstrated in early stage P301S mice. Early stage Nlrp3 +/+ xP301S: n = 23, Nlrp3 −/− xP301S: n = 27; late-stage Nlrp3 +/+ xP301S: n = 18, Nlrp3 −/− xP301S: n = 19. ** p < 0.01 by paired t -test of age-matched groups. (B) No effect of GSDMD on plasma NF-L levels were observed in the tau transgenic P301S mouse model. WT: n = 17; Early stage Nlrp3 +/+ xP301S: n = 9, Nlrp3 −/− xP301S: n = 21; Late-stage Nlrp3 +/+ xP301S: n = 27, Nlrp3 −/− xP301S: n = 19. No significance by unpaired t -test of age-matched groups.
    Figure Legend Snippet: Late-stage Nlrp3 effect on neurofilament levels and no effect of Gsdmd in P301S mice. (A) Neurofilament light (NF-L) levels were quantified in plasma of Nlrp3 xP301S mice as a surrogate marker for neurodegeneration in the CNS. At late stage, NF-L levels were significantly reduced in Nlrp3 knockout mice, compared to age-related Nlrp3 WT mice. No effect was demonstrated in early stage P301S mice. Early stage Nlrp3 +/+ xP301S: n = 23, Nlrp3 −/− xP301S: n = 27; late-stage Nlrp3 +/+ xP301S: n = 18, Nlrp3 −/− xP301S: n = 19. ** p < 0.01 by paired t -test of age-matched groups. (B) No effect of GSDMD on plasma NF-L levels were observed in the tau transgenic P301S mouse model. WT: n = 17; Early stage Nlrp3 +/+ xP301S: n = 9, Nlrp3 −/− xP301S: n = 21; Late-stage Nlrp3 +/+ xP301S: n = 27, Nlrp3 −/− xP301S: n = 19. No significance by unpaired t -test of age-matched groups.

    Techniques Used: Clinical Proteomics, Marker, Knock-Out, Transgenic Assay

    No effect of Nlrp3 or Gsdmd deletion on neuronal count in P301S mice. (A) The number of neurons was calculated in brain regions of Nlrp3 xP301S mice at early and late stage. No effect of Nlrp3 on NeuN levels was demonstrated in the different stages nor the different brain regions of P301S mice. Early stage Nlrp3 +/+ xP301S: n = ±24, Nlrp3 −/− xP301S: n = ±26; late-stage Nlrp3 +/+ xP301S: n = 18, Nlrp3 −/− xP301S: n = ±19. No significance by unpaired t -test of age-matched groups. (B) Immunohistochemistry with NeuN antibody was also performed on early and late-stage Gsdmd −/− xP301S vs. Gsdmd +/+ xP301S, demonstrating no effect of GSDMD. Early stage Gsdmd +/+ xP301S: n = 10, Gsdmd −/− xP301S: n = ±12; Late-stage Gsdmd +/+ xP301S: n = ±20, Gsdmd −/− xP301S: n = ±15. No significance by unpaired t -test of age-matched groups.
    Figure Legend Snippet: No effect of Nlrp3 or Gsdmd deletion on neuronal count in P301S mice. (A) The number of neurons was calculated in brain regions of Nlrp3 xP301S mice at early and late stage. No effect of Nlrp3 on NeuN levels was demonstrated in the different stages nor the different brain regions of P301S mice. Early stage Nlrp3 +/+ xP301S: n = ±24, Nlrp3 −/− xP301S: n = ±26; late-stage Nlrp3 +/+ xP301S: n = 18, Nlrp3 −/− xP301S: n = ±19. No significance by unpaired t -test of age-matched groups. (B) Immunohistochemistry with NeuN antibody was also performed on early and late-stage Gsdmd −/− xP301S vs. Gsdmd +/+ xP301S, demonstrating no effect of GSDMD. Early stage Gsdmd +/+ xP301S: n = 10, Gsdmd −/− xP301S: n = ±12; Late-stage Gsdmd +/+ xP301S: n = ±20, Gsdmd −/− xP301S: n = ±15. No significance by unpaired t -test of age-matched groups.

    Techniques Used: Immunohistochemistry

    No impact of Gsdmd and Nlrp3 deficiency on plasma IL-18 levels in P301S mice. (A) Mesoscale measurement of pro-inflammatory IL-18 levels in plasma of P301S mice. No significant difference between Nlrp3 knockout mice vs. Nlrp3 WT mice in early and late-stage P301S mice. Early stage Nlrp3 +/+ xP301S: n = 18, Nlrp3 −/− xP301S n = 26; Late-stage Nlrp3 +/+ xP301S: n = 16, Nlrp3 −/− xP301S: n = 18. No significance by paired t -test of age-matched groups. (B) IL-18 concentrations were additionally quantified in plasma of early and late-stage Gsdmd −/− xP301S vs. Gsdmd +/+ xP301S, demonstrating no effect of GSDMD. WT: n = 15; Early stage Nlrp3 +/+ xP301S: n = 8, Nlrp3 −/− xP301S: n = 21; Late-stage Nlrp3 +/+ xP301S: n = 26, Nlrp3 −/− xP301S: n = 19. No significance by paired t -test of age-matched groups.
    Figure Legend Snippet: No impact of Gsdmd and Nlrp3 deficiency on plasma IL-18 levels in P301S mice. (A) Mesoscale measurement of pro-inflammatory IL-18 levels in plasma of P301S mice. No significant difference between Nlrp3 knockout mice vs. Nlrp3 WT mice in early and late-stage P301S mice. Early stage Nlrp3 +/+ xP301S: n = 18, Nlrp3 −/− xP301S n = 26; Late-stage Nlrp3 +/+ xP301S: n = 16, Nlrp3 −/− xP301S: n = 18. No significance by paired t -test of age-matched groups. (B) IL-18 concentrations were additionally quantified in plasma of early and late-stage Gsdmd −/− xP301S vs. Gsdmd +/+ xP301S, demonstrating no effect of GSDMD. WT: n = 15; Early stage Nlrp3 +/+ xP301S: n = 8, Nlrp3 −/− xP301S: n = 21; Late-stage Nlrp3 +/+ xP301S: n = 26, Nlrp3 −/− xP301S: n = 19. No significance by paired t -test of age-matched groups.

    Techniques Used: Clinical Proteomics, Knock-Out



    Similar Products

    small molecule inhibitors of nlrp3  (Nodthera Inc)
    90
    Nodthera Inc small molecule inhibitors of nlrp3
    The different pathways cellular stressors act through to cause <t>NLRP3</t> inflammasome priming and activation, including the specific DAMPs they stimulate and the associated receptors they bind to. This diagram summarises information from various publications [ , , , , , , , ]. Figure created using Mural diagramming software.
    Small Molecule Inhibitors Of Nlrp3, supplied by Nodthera Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nlrp3+small+molecule+inhibitor/pmc12013246-244-10-18?v=Nodthera+Inc
    Average 90 stars, based on 1 article reviews
    small molecule inhibitors of nlrp3 - by Bioz Stars, 2026-08
    90/100 stars
    		  Buy from Supplier
    nlrp3 small molecule inhibitor compound 1  (Novartis)
    90
    Novartis nlrp3 small molecule inhibitor compound 1
    <t>NLRP3</t> pathway activation in mouse organotypic slice cultures. (A) IL-1β measurement in the supernatant of OSCs stimulated with lipopolysaccharides (LPS) and nigericin and treated with NLRP3 small molecule inhibitor (MCC950 or Compound 1). Elevated IL-1β levels in LPS + nigericin condition, which are significantly reduced by increasing concentration of NLRP3 inhibitors. Figure represents two independent experiments combined to increase the replicates per condition. Quantitative data are shown as individual datapoint, mean with standard error. PBS and LPS n = 16, Nigericin: n = 10, 10 nM, Compound 1: 100 nM ( n = 3), 300 nM ( n = 3), 10 μM ( n = 4); MCC950: 10 nM ( n = 3), 300 nM ( n = 4), 10 μM ( n = 2). (B) OSCs supernatant shows elevated IL-1β levels after K18 seeding, which are significantly decreased by addition of 1 μM NLRP3 small molecule inhibitor called JNJ81977038. Data are shown as individual datapoint, mean with standard error. Significance **** p < 0.0001 by one-way ANOVA with multiple comparisons test.
    Nlrp3 Small Molecule Inhibitor Compound 1, supplied by Novartis, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nlrp3+small+molecule+inhibitor/pmc11458539-140-8-18?v=Novartis
    Average 90 stars, based on 1 article reviews
    nlrp3 small molecule inhibitor compound 1 - by Bioz Stars, 2026-08
    90/100 stars
    		  Buy from Supplier
    nlrp3 small molecule inhibitor  (Novartis)
    86
    Novartis nlrp3 small molecule inhibitor
    FIGURE 1 <t>NLRP3</t> pathway activation in mouse organotypic slice cultures. (A) IL-1β measurement in the supernatant of OSCs stimulated with lipopolysaccharides (LPS) and nigericin and treated with NLRP3 small molecule inhibitor (MCC950 or Compound 1). Elevated IL-1β levels in LPS + nigericin condition, which are significantly reduced by increasing concentration of NLRP3 inhibitors. Figure represents two independent experiments combined to increase the replicates per condition. Quantitative data are shown as individual datapoint, mean with standard error. PBS and LPS n = 16, Nigericin: n = 10, 10 nM, Compound 1: 100 nM (n = 3), 300 nM (n = 3), 10 μM (n = 4); MCC950: 10 nM (n = 3), 300 nM (n = 4), 10 μM (n = 2). (B) OSCs supernatant shows elevated IL-1β levels after K18 seeding, which are significantly decreased by addition of 1 μM NLRP3 small molecule inhibitor called JNJ81977038. Data are shown as individual datapoint, mean with standard error. Significance ****p < 0.0001 by one-way ANOVA with multiple comparisons test.
    Nlrp3 Small Molecule Inhibitor, supplied by Novartis, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nlrp3+small+molecule+inhibitor/pm39381137-155-8-18?v=Novartis
    Average 86 stars, based on 1 article reviews
    nlrp3 small molecule inhibitor - by Bioz Stars, 2026-08
    86/100 stars
    		  Buy from Supplier
    small molecule nlrp3 inhibitors  (Inflazome)
    90
    Inflazome small molecule nlrp3 inhibitors
    FIGURE 1 <t>NLRP3</t> pathway activation in mouse organotypic slice cultures. (A) IL-1β measurement in the supernatant of OSCs stimulated with lipopolysaccharides (LPS) and nigericin and treated with NLRP3 small molecule inhibitor (MCC950 or Compound 1). Elevated IL-1β levels in LPS + nigericin condition, which are significantly reduced by increasing concentration of NLRP3 inhibitors. Figure represents two independent experiments combined to increase the replicates per condition. Quantitative data are shown as individual datapoint, mean with standard error. PBS and LPS n = 16, Nigericin: n = 10, 10 nM, Compound 1: 100 nM (n = 3), 300 nM (n = 3), 10 μM (n = 4); MCC950: 10 nM (n = 3), 300 nM (n = 4), 10 μM (n = 2). (B) OSCs supernatant shows elevated IL-1β levels after K18 seeding, which are significantly decreased by addition of 1 μM NLRP3 small molecule inhibitor called JNJ81977038. Data are shown as individual datapoint, mean with standard error. Significance ****p < 0.0001 by one-way ANOVA with multiple comparisons test.
    Small Molecule Nlrp3 Inhibitors, supplied by Inflazome, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nlrp3+small+molecule+inhibitor/pmc10019778-415-9-23?v=Inflazome
    Average 90 stars, based on 1 article reviews
    small molecule nlrp3 inhibitors - by Bioz Stars, 2026-08
    90/100 stars
    		  Buy from Supplier
    small molecule inhibitors of the nlrp3 inflammasome  (Inflazome)
    90
    Inflazome small molecule inhibitors of the nlrp3 inflammasome
    FIGURE 1 <t>NLRP3</t> pathway activation in mouse organotypic slice cultures. (A) IL-1β measurement in the supernatant of OSCs stimulated with lipopolysaccharides (LPS) and nigericin and treated with NLRP3 small molecule inhibitor (MCC950 or Compound 1). Elevated IL-1β levels in LPS + nigericin condition, which are significantly reduced by increasing concentration of NLRP3 inhibitors. Figure represents two independent experiments combined to increase the replicates per condition. Quantitative data are shown as individual datapoint, mean with standard error. PBS and LPS n = 16, Nigericin: n = 10, 10 nM, Compound 1: 100 nM (n = 3), 300 nM (n = 3), 10 μM (n = 4); MCC950: 10 nM (n = 3), 300 nM (n = 4), 10 μM (n = 2). (B) OSCs supernatant shows elevated IL-1β levels after K18 seeding, which are significantly decreased by addition of 1 μM NLRP3 small molecule inhibitor called JNJ81977038. Data are shown as individual datapoint, mean with standard error. Significance ****p < 0.0001 by one-way ANOVA with multiple comparisons test.
    Small Molecule Inhibitors Of The Nlrp3 Inflammasome, supplied by Inflazome, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nlrp3+small+molecule+inhibitor/pm33397151-8-16-20?v=Inflazome
    Average 90 stars, based on 1 article reviews
    small molecule inhibitors of the nlrp3 inflammasome - by Bioz Stars, 2026-08
    90/100 stars
    		  Buy from Supplier
    small-molecule nlrp3 inhibitors  (Nodthera Inc)
    90
    Nodthera Inc small-molecule nlrp3 inhibitors
    <t> NLRP3 </t> inflammasome-targeted therapeutics in development.
    Small Molecule Nlrp3 Inhibitors, supplied by Nodthera Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nlrp3+small+molecule+inhibitor/pmc07324760-3-5-3?v=Nodthera+Inc
    Average 90 stars, based on 1 article reviews
    small-molecule nlrp3 inhibitors - by Bioz Stars, 2026-08
    90/100 stars
    		  Buy from Supplier
    small-molecule nlrp3 inhibitors  (Inflazome)
    90
    Inflazome small-molecule nlrp3 inhibitors
    <t> NLRP3 </t> inflammasome-targeted therapeutics in development.
    Small Molecule Nlrp3 Inhibitors, supplied by Inflazome, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nlrp3+small+molecule+inhibitor/pmc07324760-7-7-5?v=Inflazome
    Average 90 stars, based on 1 article reviews
    small-molecule nlrp3 inhibitors - by Bioz Stars, 2026-08
    90/100 stars
    		  Buy from Supplier
    small-molecule nlrp3 inhibitors  (Olatec Therapeutics LLC)
    90
    Olatec Therapeutics LLC small-molecule nlrp3 inhibitors
    <t> NLRP3 </t> inflammasome-targeted therapeutics in development.
    Small Molecule Nlrp3 Inhibitors, supplied by Olatec Therapeutics LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nlrp3+small+molecule+inhibitor/10__1021_slash_cen___09807___cover-144-1-3?v=Olatec+Therapeutics+LLC
    Average 90 stars, based on 1 article reviews
    small-molecule nlrp3 inhibitors - by Bioz Stars, 2026-08
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    The different pathways cellular stressors act through to cause NLRP3 inflammasome priming and activation, including the specific DAMPs they stimulate and the associated receptors they bind to. This diagram summarises information from various publications [ , , , , , , , ]. Figure created using Mural diagramming software.

    Journal: American Journal of Reproductive Immunology

    Article Title: Understanding a Potential Role for the NLRP3 Inflammasome in Placenta‐Mediated Pregnancy Complications

    doi: 10.1111/aji.70077

    Figure Lengend Snippet: The different pathways cellular stressors act through to cause NLRP3 inflammasome priming and activation, including the specific DAMPs they stimulate and the associated receptors they bind to. This diagram summarises information from various publications [ , , , , , , , ]. Figure created using Mural diagramming software.

    Article Snippet: Highly potent (nM IC 50 values) small molecule inhibitors of NLRP3 have recently been discovered (Table ) by NodThera and Novartis pharmaceutical companies.

    Techniques: Activation Assay, Software

    The structure of the NLRP3 trimeric protein and the components of the NLRP3 inflammasome complex. The stimuli for the priming and activation phase, as well as the subsequent downstream signalling events following NLRP3 inflammasome formation are shown. The products resulting from NLRP3 inflammasome activation are also depicted.

    Journal: American Journal of Reproductive Immunology

    Article Title: Understanding a Potential Role for the NLRP3 Inflammasome in Placenta‐Mediated Pregnancy Complications

    doi: 10.1111/aji.70077

    Figure Lengend Snippet: The structure of the NLRP3 trimeric protein and the components of the NLRP3 inflammasome complex. The stimuli for the priming and activation phase, as well as the subsequent downstream signalling events following NLRP3 inflammasome formation are shown. The products resulting from NLRP3 inflammasome activation are also depicted.

    Article Snippet: Highly potent (nM IC 50 values) small molecule inhibitors of NLRP3 have recently been discovered (Table ) by NodThera and Novartis pharmaceutical companies.

    Techniques: Activation Assay

    A summary of the literature available on the expression of the NLRP3 inflammasome in inflammatory disorders of pregnancy.

    Journal: American Journal of Reproductive Immunology

    Article Title: Understanding a Potential Role for the NLRP3 Inflammasome in Placenta‐Mediated Pregnancy Complications

    doi: 10.1111/aji.70077

    Figure Lengend Snippet: A summary of the literature available on the expression of the NLRP3 inflammasome in inflammatory disorders of pregnancy.

    Article Snippet: Highly potent (nM IC 50 values) small molecule inhibitors of NLRP3 have recently been discovered (Table ) by NodThera and Novartis pharmaceutical companies.

    Techniques: Expressing, Control, Isolation, Real-time Polymerase Chain Reaction, Enzyme-linked Immunosorbent Assay, Activity Assay, Medications, RNA Sequencing

    Summary of the literature available on sterile inflammation markers (DAMPs), their interactions with the NLRP3 inflammasome, and their presence in inflammatory disorders of pregnancy.

    Journal: American Journal of Reproductive Immunology

    Article Title: Understanding a Potential Role for the NLRP3 Inflammasome in Placenta‐Mediated Pregnancy Complications

    doi: 10.1111/aji.70077

    Figure Lengend Snippet: Summary of the literature available on sterile inflammation markers (DAMPs), their interactions with the NLRP3 inflammasome, and their presence in inflammatory disorders of pregnancy.

    Article Snippet: Highly potent (nM IC 50 values) small molecule inhibitors of NLRP3 have recently been discovered (Table ) by NodThera and Novartis pharmaceutical companies.

    Techniques: Sterility, Enzyme-linked Immunosorbent Assay, Control, Activity Assay, Flow Cytometry, Derivative Assay, Activation Assay, CRISPR, Expressing, Clinical Proteomics, Saline

    Potent small molecule and biological inhibitors of the NLRP3 inflammasome.

    Journal: American Journal of Reproductive Immunology

    Article Title: Understanding a Potential Role for the NLRP3 Inflammasome in Placenta‐Mediated Pregnancy Complications

    doi: 10.1111/aji.70077

    Figure Lengend Snippet: Potent small molecule and biological inhibitors of the NLRP3 inflammasome.

    Article Snippet: Highly potent (nM IC 50 values) small molecule inhibitors of NLRP3 have recently been discovered (Table ) by NodThera and Novartis pharmaceutical companies.

    Techniques: Inhibition, Binding Assay, Activation Assay, Clinical Proteomics

    NLRP3 pathway activation in mouse organotypic slice cultures. (A) IL-1β measurement in the supernatant of OSCs stimulated with lipopolysaccharides (LPS) and nigericin and treated with NLRP3 small molecule inhibitor (MCC950 or Compound 1). Elevated IL-1β levels in LPS + nigericin condition, which are significantly reduced by increasing concentration of NLRP3 inhibitors. Figure represents two independent experiments combined to increase the replicates per condition. Quantitative data are shown as individual datapoint, mean with standard error. PBS and LPS n = 16, Nigericin: n = 10, 10 nM, Compound 1: 100 nM ( n = 3), 300 nM ( n = 3), 10 μM ( n = 4); MCC950: 10 nM ( n = 3), 300 nM ( n = 4), 10 μM ( n = 2). (B) OSCs supernatant shows elevated IL-1β levels after K18 seeding, which are significantly decreased by addition of 1 μM NLRP3 small molecule inhibitor called JNJ81977038. Data are shown as individual datapoint, mean with standard error. Significance **** p < 0.0001 by one-way ANOVA with multiple comparisons test.

    Journal: Frontiers in Aging Neuroscience

    Article Title: NLRP3 inflammasome activation and pyroptosis are dispensable for tau pathology

    doi: 10.3389/fnagi.2024.1459134

    Figure Lengend Snippet: NLRP3 pathway activation in mouse organotypic slice cultures. (A) IL-1β measurement in the supernatant of OSCs stimulated with lipopolysaccharides (LPS) and nigericin and treated with NLRP3 small molecule inhibitor (MCC950 or Compound 1). Elevated IL-1β levels in LPS + nigericin condition, which are significantly reduced by increasing concentration of NLRP3 inhibitors. Figure represents two independent experiments combined to increase the replicates per condition. Quantitative data are shown as individual datapoint, mean with standard error. PBS and LPS n = 16, Nigericin: n = 10, 10 nM, Compound 1: 100 nM ( n = 3), 300 nM ( n = 3), 10 μM ( n = 4); MCC950: 10 nM ( n = 3), 300 nM ( n = 4), 10 μM ( n = 2). (B) OSCs supernatant shows elevated IL-1β levels after K18 seeding, which are significantly decreased by addition of 1 μM NLRP3 small molecule inhibitor called JNJ81977038. Data are shown as individual datapoint, mean with standard error. Significance **** p < 0.0001 by one-way ANOVA with multiple comparisons test.

    Article Snippet: Slices were treated with 1 μM of a NLRP3 small molecule inhibitor [Compound 1; example 49 of WO2020234715A1 (Novartis AG)].

    Techniques: Activation Assay, Concentration Assay

    No effect of Nlrp3 knockout on tau pathology by IHC. (A) AT100 immunohistochemistry demonstrated no significant effect on tau phosphorylation/aggregation in all analyzed regions of late-stage Nlrp3 −/− xP301S vs. Nlrp3 +/+ xP301S mice. Brain stem, spinal cord, and midbrain showed a trend in reduced pathology for Nlrp3 deficiency, which was not significant. Early stage P301S mice displayed much lower aggregated tau levels compared to late-stage animals and no effect of Nlrp3 deletion on tauopathy was observed at this age in any of the regions analyzed. Image analysis data are shown as mean + individual values for each animal (average of two sections/animal). Early stage Nlrp3 +/+ xP301S: n = 24, Nlrp3 −/− xP301S: n = 26; Late-stage Nlrp3 +/+ xP301S: n = 18, Nlrp3 −/− xP301S: n = 19. No significance by unpaired t -test of age-matched groups. (B) Representative images of the AT00 IHC staining are demonstrated. Scale bars: 2.5 mm (overview images), 100 μm (higher magnification images). (C) Biochemical analysis of tau pathology in brainstem of Nlrp3 xP301S mice. Aggregated tau levels were not significantly reduced in the sarcosyl-insoluble fraction or total homogenate of the brainstem of late-stage Nlrp3 −/− vs. Nlrp3 +/+ xP301S mice. Early stage Nlrp3 +/+ xP301S: n = 23, Nlrp3 −/− xP301S: n = 25; Late-stage Nlrp3 +/+ xP301S: n = 16, Nlrp3 −/− xP301S: n = 16. Data are expressed as mean + individual values of each animal tested (values = average of two sections/mouse).

    Journal: Frontiers in Aging Neuroscience

    Article Title: NLRP3 inflammasome activation and pyroptosis are dispensable for tau pathology

    doi: 10.3389/fnagi.2024.1459134

    Figure Lengend Snippet: No effect of Nlrp3 knockout on tau pathology by IHC. (A) AT100 immunohistochemistry demonstrated no significant effect on tau phosphorylation/aggregation in all analyzed regions of late-stage Nlrp3 −/− xP301S vs. Nlrp3 +/+ xP301S mice. Brain stem, spinal cord, and midbrain showed a trend in reduced pathology for Nlrp3 deficiency, which was not significant. Early stage P301S mice displayed much lower aggregated tau levels compared to late-stage animals and no effect of Nlrp3 deletion on tauopathy was observed at this age in any of the regions analyzed. Image analysis data are shown as mean + individual values for each animal (average of two sections/animal). Early stage Nlrp3 +/+ xP301S: n = 24, Nlrp3 −/− xP301S: n = 26; Late-stage Nlrp3 +/+ xP301S: n = 18, Nlrp3 −/− xP301S: n = 19. No significance by unpaired t -test of age-matched groups. (B) Representative images of the AT00 IHC staining are demonstrated. Scale bars: 2.5 mm (overview images), 100 μm (higher magnification images). (C) Biochemical analysis of tau pathology in brainstem of Nlrp3 xP301S mice. Aggregated tau levels were not significantly reduced in the sarcosyl-insoluble fraction or total homogenate of the brainstem of late-stage Nlrp3 −/− vs. Nlrp3 +/+ xP301S mice. Early stage Nlrp3 +/+ xP301S: n = 23, Nlrp3 −/− xP301S: n = 25; Late-stage Nlrp3 +/+ xP301S: n = 16, Nlrp3 −/− xP301S: n = 16. Data are expressed as mean + individual values of each animal tested (values = average of two sections/mouse).

    Article Snippet: Slices were treated with 1 μM of a NLRP3 small molecule inhibitor [Compound 1; example 49 of WO2020234715A1 (Novartis AG)].

    Techniques: Knock-Out, Immunohistochemistry, Phospho-proteomics

    AT100 immunohistochemistry was not altered in Gsdmd deficient mice. (A) Immunohistochemistry with phospho-tau AT100 antibody showed no significant effect on tau pathology in Gsdmd xP301S mice. No significant difference is detected between Nlrp3 −/− xP301S vs. Nlrp3 +/+ xP301S mice at early and late stage. Quantitative data are shown as mean + individual values for each animal. Early stage Nlrp3 +/+ xP301S: n = ±10, Nlrp3 −/− xP301S: n = ±15; Late-stage Nlrp3 +/+ xP301S: n = ±25, Nlrp3 −/− xP301S: n = ±20. No significance by unpaired t -test of age-matched groups. (B) Representative images of brain stem, midbrain, spinal cord, and cortex are shown. The whole brain sections are displayed at 2.5 mm and the spinal cord sections are displayed at 100 μm.

    Journal: Frontiers in Aging Neuroscience

    Article Title: NLRP3 inflammasome activation and pyroptosis are dispensable for tau pathology

    doi: 10.3389/fnagi.2024.1459134

    Figure Lengend Snippet: AT100 immunohistochemistry was not altered in Gsdmd deficient mice. (A) Immunohistochemistry with phospho-tau AT100 antibody showed no significant effect on tau pathology in Gsdmd xP301S mice. No significant difference is detected between Nlrp3 −/− xP301S vs. Nlrp3 +/+ xP301S mice at early and late stage. Quantitative data are shown as mean + individual values for each animal. Early stage Nlrp3 +/+ xP301S: n = ±10, Nlrp3 −/− xP301S: n = ±15; Late-stage Nlrp3 +/+ xP301S: n = ±25, Nlrp3 −/− xP301S: n = ±20. No significance by unpaired t -test of age-matched groups. (B) Representative images of brain stem, midbrain, spinal cord, and cortex are shown. The whole brain sections are displayed at 2.5 mm and the spinal cord sections are displayed at 100 μm.

    Article Snippet: Slices were treated with 1 μM of a NLRP3 small molecule inhibitor [Compound 1; example 49 of WO2020234715A1 (Novartis AG)].

    Techniques: Immunohistochemistry

    Late-stage Nlrp3 effect on neurofilament levels and no effect of Gsdmd in P301S mice. (A) Neurofilament light (NF-L) levels were quantified in plasma of Nlrp3 xP301S mice as a surrogate marker for neurodegeneration in the CNS. At late stage, NF-L levels were significantly reduced in Nlrp3 knockout mice, compared to age-related Nlrp3 WT mice. No effect was demonstrated in early stage P301S mice. Early stage Nlrp3 +/+ xP301S: n = 23, Nlrp3 −/− xP301S: n = 27; late-stage Nlrp3 +/+ xP301S: n = 18, Nlrp3 −/− xP301S: n = 19. ** p < 0.01 by paired t -test of age-matched groups. (B) No effect of GSDMD on plasma NF-L levels were observed in the tau transgenic P301S mouse model. WT: n = 17; Early stage Nlrp3 +/+ xP301S: n = 9, Nlrp3 −/− xP301S: n = 21; Late-stage Nlrp3 +/+ xP301S: n = 27, Nlrp3 −/− xP301S: n = 19. No significance by unpaired t -test of age-matched groups.

    Journal: Frontiers in Aging Neuroscience

    Article Title: NLRP3 inflammasome activation and pyroptosis are dispensable for tau pathology

    doi: 10.3389/fnagi.2024.1459134

    Figure Lengend Snippet: Late-stage Nlrp3 effect on neurofilament levels and no effect of Gsdmd in P301S mice. (A) Neurofilament light (NF-L) levels were quantified in plasma of Nlrp3 xP301S mice as a surrogate marker for neurodegeneration in the CNS. At late stage, NF-L levels were significantly reduced in Nlrp3 knockout mice, compared to age-related Nlrp3 WT mice. No effect was demonstrated in early stage P301S mice. Early stage Nlrp3 +/+ xP301S: n = 23, Nlrp3 −/− xP301S: n = 27; late-stage Nlrp3 +/+ xP301S: n = 18, Nlrp3 −/− xP301S: n = 19. ** p < 0.01 by paired t -test of age-matched groups. (B) No effect of GSDMD on plasma NF-L levels were observed in the tau transgenic P301S mouse model. WT: n = 17; Early stage Nlrp3 +/+ xP301S: n = 9, Nlrp3 −/− xP301S: n = 21; Late-stage Nlrp3 +/+ xP301S: n = 27, Nlrp3 −/− xP301S: n = 19. No significance by unpaired t -test of age-matched groups.

    Article Snippet: Slices were treated with 1 μM of a NLRP3 small molecule inhibitor [Compound 1; example 49 of WO2020234715A1 (Novartis AG)].

    Techniques: Clinical Proteomics, Marker, Knock-Out, Transgenic Assay

    No effect of Nlrp3 or Gsdmd deletion on neuronal count in P301S mice. (A) The number of neurons was calculated in brain regions of Nlrp3 xP301S mice at early and late stage. No effect of Nlrp3 on NeuN levels was demonstrated in the different stages nor the different brain regions of P301S mice. Early stage Nlrp3 +/+ xP301S: n = ±24, Nlrp3 −/− xP301S: n = ±26; late-stage Nlrp3 +/+ xP301S: n = 18, Nlrp3 −/− xP301S: n = ±19. No significance by unpaired t -test of age-matched groups. (B) Immunohistochemistry with NeuN antibody was also performed on early and late-stage Gsdmd −/− xP301S vs. Gsdmd +/+ xP301S, demonstrating no effect of GSDMD. Early stage Gsdmd +/+ xP301S: n = 10, Gsdmd −/− xP301S: n = ±12; Late-stage Gsdmd +/+ xP301S: n = ±20, Gsdmd −/− xP301S: n = ±15. No significance by unpaired t -test of age-matched groups.

    Journal: Frontiers in Aging Neuroscience

    Article Title: NLRP3 inflammasome activation and pyroptosis are dispensable for tau pathology

    doi: 10.3389/fnagi.2024.1459134

    Figure Lengend Snippet: No effect of Nlrp3 or Gsdmd deletion on neuronal count in P301S mice. (A) The number of neurons was calculated in brain regions of Nlrp3 xP301S mice at early and late stage. No effect of Nlrp3 on NeuN levels was demonstrated in the different stages nor the different brain regions of P301S mice. Early stage Nlrp3 +/+ xP301S: n = ±24, Nlrp3 −/− xP301S: n = ±26; late-stage Nlrp3 +/+ xP301S: n = 18, Nlrp3 −/− xP301S: n = ±19. No significance by unpaired t -test of age-matched groups. (B) Immunohistochemistry with NeuN antibody was also performed on early and late-stage Gsdmd −/− xP301S vs. Gsdmd +/+ xP301S, demonstrating no effect of GSDMD. Early stage Gsdmd +/+ xP301S: n = 10, Gsdmd −/− xP301S: n = ±12; Late-stage Gsdmd +/+ xP301S: n = ±20, Gsdmd −/− xP301S: n = ±15. No significance by unpaired t -test of age-matched groups.

    Article Snippet: Slices were treated with 1 μM of a NLRP3 small molecule inhibitor [Compound 1; example 49 of WO2020234715A1 (Novartis AG)].

    Techniques: Immunohistochemistry

    No impact of Gsdmd and Nlrp3 deficiency on plasma IL-18 levels in P301S mice. (A) Mesoscale measurement of pro-inflammatory IL-18 levels in plasma of P301S mice. No significant difference between Nlrp3 knockout mice vs. Nlrp3 WT mice in early and late-stage P301S mice. Early stage Nlrp3 +/+ xP301S: n = 18, Nlrp3 −/− xP301S n = 26; Late-stage Nlrp3 +/+ xP301S: n = 16, Nlrp3 −/− xP301S: n = 18. No significance by paired t -test of age-matched groups. (B) IL-18 concentrations were additionally quantified in plasma of early and late-stage Gsdmd −/− xP301S vs. Gsdmd +/+ xP301S, demonstrating no effect of GSDMD. WT: n = 15; Early stage Nlrp3 +/+ xP301S: n = 8, Nlrp3 −/− xP301S: n = 21; Late-stage Nlrp3 +/+ xP301S: n = 26, Nlrp3 −/− xP301S: n = 19. No significance by paired t -test of age-matched groups.

    Journal: Frontiers in Aging Neuroscience

    Article Title: NLRP3 inflammasome activation and pyroptosis are dispensable for tau pathology

    doi: 10.3389/fnagi.2024.1459134

    Figure Lengend Snippet: No impact of Gsdmd and Nlrp3 deficiency on plasma IL-18 levels in P301S mice. (A) Mesoscale measurement of pro-inflammatory IL-18 levels in plasma of P301S mice. No significant difference between Nlrp3 knockout mice vs. Nlrp3 WT mice in early and late-stage P301S mice. Early stage Nlrp3 +/+ xP301S: n = 18, Nlrp3 −/− xP301S n = 26; Late-stage Nlrp3 +/+ xP301S: n = 16, Nlrp3 −/− xP301S: n = 18. No significance by paired t -test of age-matched groups. (B) IL-18 concentrations were additionally quantified in plasma of early and late-stage Gsdmd −/− xP301S vs. Gsdmd +/+ xP301S, demonstrating no effect of GSDMD. WT: n = 15; Early stage Nlrp3 +/+ xP301S: n = 8, Nlrp3 −/− xP301S: n = 21; Late-stage Nlrp3 +/+ xP301S: n = 26, Nlrp3 −/− xP301S: n = 19. No significance by paired t -test of age-matched groups.

    Article Snippet: Slices were treated with 1 μM of a NLRP3 small molecule inhibitor [Compound 1; example 49 of WO2020234715A1 (Novartis AG)].

    Techniques: Clinical Proteomics, Knock-Out

    FIGURE 1 NLRP3 pathway activation in mouse organotypic slice cultures. (A) IL-1β measurement in the supernatant of OSCs stimulated with lipopolysaccharides (LPS) and nigericin and treated with NLRP3 small molecule inhibitor (MCC950 or Compound 1). Elevated IL-1β levels in LPS + nigericin condition, which are significantly reduced by increasing concentration of NLRP3 inhibitors. Figure represents two independent experiments combined to increase the replicates per condition. Quantitative data are shown as individual datapoint, mean with standard error. PBS and LPS n = 16, Nigericin: n = 10, 10 nM, Compound 1: 100 nM (n = 3), 300 nM (n = 3), 10 μM (n = 4); MCC950: 10 nM (n = 3), 300 nM (n = 4), 10 μM (n = 2). (B) OSCs supernatant shows elevated IL-1β levels after K18 seeding, which are significantly decreased by addition of 1 μM NLRP3 small molecule inhibitor called JNJ81977038. Data are shown as individual datapoint, mean with standard error. Significance ****p < 0.0001 by one-way ANOVA with multiple comparisons test.

    Journal: Frontiers in aging neuroscience

    Article Title: NLRP3 inflammasome activation and pyroptosis are dispensable for tau pathology.

    doi: 10.3389/fnagi.2024.1459134

    Figure Lengend Snippet: FIGURE 1 NLRP3 pathway activation in mouse organotypic slice cultures. (A) IL-1β measurement in the supernatant of OSCs stimulated with lipopolysaccharides (LPS) and nigericin and treated with NLRP3 small molecule inhibitor (MCC950 or Compound 1). Elevated IL-1β levels in LPS + nigericin condition, which are significantly reduced by increasing concentration of NLRP3 inhibitors. Figure represents two independent experiments combined to increase the replicates per condition. Quantitative data are shown as individual datapoint, mean with standard error. PBS and LPS n = 16, Nigericin: n = 10, 10 nM, Compound 1: 100 nM (n = 3), 300 nM (n = 3), 10 μM (n = 4); MCC950: 10 nM (n = 3), 300 nM (n = 4), 10 μM (n = 2). (B) OSCs supernatant shows elevated IL-1β levels after K18 seeding, which are significantly decreased by addition of 1 μM NLRP3 small molecule inhibitor called JNJ81977038. Data are shown as individual datapoint, mean with standard error. Significance ****p < 0.0001 by one-way ANOVA with multiple comparisons test.

    Article Snippet: Slices were treated with 1 μM of a NLRP3 small molecule inhibitor [Compound 1; example 49 of WO2020234715A1 (Novartis AG)].

    Techniques: Activation Assay, Concentration Assay

    FIGURE 2 No effect of Nlrp3 knockout on tau pathology by IHC. (A) AT100 immunohistochemistry demonstrated no significant effect on tau phosphorylation/ aggregation in all analyzed regions of late-stage Nlrp3−/−xP301S vs. Nlrp3+/+xP301S mice. Brain stem, spinal cord, and midbrain showed a trend in reduced pathology for Nlrp3 deficiency, which was not significant. Early stage P301S mice displayed much lower aggregated tau levels compared to late-stage animals and no effect of Nlrp3 deletion on tauopathy was observed at this age in any of the regions analyzed. Image analysis data are shown as mean + individual values for each animal (average of two sections/animal). Early stage Nlrp3+/+xP301S: n = 24, Nlrp3−/−xP301S: n = 26; Late-stage Nlrp3+/+xP301S: n = 18, Nlrp3−/−xP301S: n = 19. No significance by unpaired t-test of age-matched groups. (B) Representative images of the AT00 IHC staining are demonstrated. Scale bars: 2.5 mm (overview images), 100 μm (higher magnification images). (C) Biochemical analysis of tau pathology in brainstem of Nlrp3xP301S mice. Aggregated tau levels were not significantly reduced in the sarcosyl-insoluble fraction or total homogenate of the brainstem of late-stage Nlrp3−/− vs. Nlrp3+/+xP301S mice. Early stage Nlrp3+/+xP301S: n = 23, Nlrp3−/−xP301S: n = 25; Late-stage Nlrp3+/+xP301S: n = 16, Nlrp3−/−xP301S: n = 16. Data are expressed as mean + individual values of each animal tested (values = average of two sections/mouse).

    Journal: Frontiers in aging neuroscience

    Article Title: NLRP3 inflammasome activation and pyroptosis are dispensable for tau pathology.

    doi: 10.3389/fnagi.2024.1459134

    Figure Lengend Snippet: FIGURE 2 No effect of Nlrp3 knockout on tau pathology by IHC. (A) AT100 immunohistochemistry demonstrated no significant effect on tau phosphorylation/ aggregation in all analyzed regions of late-stage Nlrp3−/−xP301S vs. Nlrp3+/+xP301S mice. Brain stem, spinal cord, and midbrain showed a trend in reduced pathology for Nlrp3 deficiency, which was not significant. Early stage P301S mice displayed much lower aggregated tau levels compared to late-stage animals and no effect of Nlrp3 deletion on tauopathy was observed at this age in any of the regions analyzed. Image analysis data are shown as mean + individual values for each animal (average of two sections/animal). Early stage Nlrp3+/+xP301S: n = 24, Nlrp3−/−xP301S: n = 26; Late-stage Nlrp3+/+xP301S: n = 18, Nlrp3−/−xP301S: n = 19. No significance by unpaired t-test of age-matched groups. (B) Representative images of the AT00 IHC staining are demonstrated. Scale bars: 2.5 mm (overview images), 100 μm (higher magnification images). (C) Biochemical analysis of tau pathology in brainstem of Nlrp3xP301S mice. Aggregated tau levels were not significantly reduced in the sarcosyl-insoluble fraction or total homogenate of the brainstem of late-stage Nlrp3−/− vs. Nlrp3+/+xP301S mice. Early stage Nlrp3+/+xP301S: n = 23, Nlrp3−/−xP301S: n = 25; Late-stage Nlrp3+/+xP301S: n = 16, Nlrp3−/−xP301S: n = 16. Data are expressed as mean + individual values of each animal tested (values = average of two sections/mouse).

    Article Snippet: Slices were treated with 1 μM of a NLRP3 small molecule inhibitor [Compound 1; example 49 of WO2020234715A1 (Novartis AG)].

    Techniques: Knock-Out, Immunohistochemistry, Phospho-proteomics

    FIGURE 4 AT100 immunohistochemistry was not altered in Gsdmd deficient mice. (A) Immunohistochemistry with phospho-tau AT100 antibody showed no significant effect on tau pathology in GsdmdxP301S mice. No significant difference is detected between Nlrp3−/−xP301S vs. Nlrp3+/+xP301S mice at early and late stage. Quantitative data are shown as mean + individual values for each animal. Early stage Nlrp3+/+xP301S: n = ±10, Nlrp3−/−xP301S: n = ±15; Late-stage Nlrp3+/+xP301S: n = ±25, Nlrp3−/−xP301S: n = ±20. No significance by unpaired t-test of age-matched groups. (B) Representative images of brain stem, midbrain, spinal cord, and cortex are shown. The whole brain sections are displayed at 2.5 mm and the spinal cord sections are displayed at 100 μm.

    Journal: Frontiers in aging neuroscience

    Article Title: NLRP3 inflammasome activation and pyroptosis are dispensable for tau pathology.

    doi: 10.3389/fnagi.2024.1459134

    Figure Lengend Snippet: FIGURE 4 AT100 immunohistochemistry was not altered in Gsdmd deficient mice. (A) Immunohistochemistry with phospho-tau AT100 antibody showed no significant effect on tau pathology in GsdmdxP301S mice. No significant difference is detected between Nlrp3−/−xP301S vs. Nlrp3+/+xP301S mice at early and late stage. Quantitative data are shown as mean + individual values for each animal. Early stage Nlrp3+/+xP301S: n = ±10, Nlrp3−/−xP301S: n = ±15; Late-stage Nlrp3+/+xP301S: n = ±25, Nlrp3−/−xP301S: n = ±20. No significance by unpaired t-test of age-matched groups. (B) Representative images of brain stem, midbrain, spinal cord, and cortex are shown. The whole brain sections are displayed at 2.5 mm and the spinal cord sections are displayed at 100 μm.

    Article Snippet: Slices were treated with 1 μM of a NLRP3 small molecule inhibitor [Compound 1; example 49 of WO2020234715A1 (Novartis AG)].

    Techniques: Immunohistochemistry

    FIGURE 5 Late-stage Nlrp3 effect on neurofilament levels and no effect of Gsdmd in P301S mice. (A) Neurofilament light (NF-L) levels were quantified in plasma of Nlrp3xP301S mice as a surrogate marker for neurodegeneration in the CNS. At late stage, NF-L levels were significantly reduced in Nlrp3 knockout mice, compared to age-related Nlrp3 WT mice. No effect was demonstrated in early stage P301S mice. Early stage Nlrp3+/+xP301S: n = 23, Nlrp3−/−xP301S: n = 27; late-stage Nlrp3+/+xP301S: n = 18, Nlrp3−/−xP301S: n = 19. **p < 0.01 by paired t-test of age-matched groups. (B) No effect of GSDMD on plasma NF-L levels were observed in the tau transgenic P301S mouse model. WT: n = 17; Early stage Nlrp3+/+xP301S: n = 9, Nlrp3−/−xP301S: n = 21; Late-stage Nlrp3+/+xP301S: n = 27, Nlrp3−/−xP301S: n = 19. No significance by unpaired t-test of age-matched groups.

    Journal: Frontiers in aging neuroscience

    Article Title: NLRP3 inflammasome activation and pyroptosis are dispensable for tau pathology.

    doi: 10.3389/fnagi.2024.1459134

    Figure Lengend Snippet: FIGURE 5 Late-stage Nlrp3 effect on neurofilament levels and no effect of Gsdmd in P301S mice. (A) Neurofilament light (NF-L) levels were quantified in plasma of Nlrp3xP301S mice as a surrogate marker for neurodegeneration in the CNS. At late stage, NF-L levels were significantly reduced in Nlrp3 knockout mice, compared to age-related Nlrp3 WT mice. No effect was demonstrated in early stage P301S mice. Early stage Nlrp3+/+xP301S: n = 23, Nlrp3−/−xP301S: n = 27; late-stage Nlrp3+/+xP301S: n = 18, Nlrp3−/−xP301S: n = 19. **p < 0.01 by paired t-test of age-matched groups. (B) No effect of GSDMD on plasma NF-L levels were observed in the tau transgenic P301S mouse model. WT: n = 17; Early stage Nlrp3+/+xP301S: n = 9, Nlrp3−/−xP301S: n = 21; Late-stage Nlrp3+/+xP301S: n = 27, Nlrp3−/−xP301S: n = 19. No significance by unpaired t-test of age-matched groups.

    Article Snippet: Slices were treated with 1 μM of a NLRP3 small molecule inhibitor [Compound 1; example 49 of WO2020234715A1 (Novartis AG)].

    Techniques: Clinical Proteomics, Marker, Knock-Out, Transgenic Assay

    FIGURE 6 No effect of Nlrp3 or Gsdmd deletion on neuronal count in P301S mice. (A) The number of neurons was calculated in brain regions of Nlrp3xP301S mice at early and late stage. No effect of Nlrp3 on NeuN levels was demonstrated in the different stages nor the different brain regions of P301S mice. Early stage Nlrp3+/+xP301S: n = ±24, Nlrp3−/−xP301S: n = ±26; late-stage Nlrp3+/+xP301S: n = 18, Nlrp3−/−xP301S: n = ±19. No significance by unpaired t-test of age- matched groups. (B) Immunohistochemistry with NeuN antibody was also performed on early and late-stage Gsdmd−/−xP301S vs. Gsdmd+/+xP301S, demonstrating no effect of GSDMD. Early stage Gsdmd+/+xP301S: n = 10, Gsdmd−/−xP301S: n = ±12; Late-stage Gsdmd+/+xP301S: n = ±20, Gsdmd−/−xP301S: n = ±15. No significance by unpaired t-test of age-matched groups.

    Journal: Frontiers in aging neuroscience

    Article Title: NLRP3 inflammasome activation and pyroptosis are dispensable for tau pathology.

    doi: 10.3389/fnagi.2024.1459134

    Figure Lengend Snippet: FIGURE 6 No effect of Nlrp3 or Gsdmd deletion on neuronal count in P301S mice. (A) The number of neurons was calculated in brain regions of Nlrp3xP301S mice at early and late stage. No effect of Nlrp3 on NeuN levels was demonstrated in the different stages nor the different brain regions of P301S mice. Early stage Nlrp3+/+xP301S: n = ±24, Nlrp3−/−xP301S: n = ±26; late-stage Nlrp3+/+xP301S: n = 18, Nlrp3−/−xP301S: n = ±19. No significance by unpaired t-test of age- matched groups. (B) Immunohistochemistry with NeuN antibody was also performed on early and late-stage Gsdmd−/−xP301S vs. Gsdmd+/+xP301S, demonstrating no effect of GSDMD. Early stage Gsdmd+/+xP301S: n = 10, Gsdmd−/−xP301S: n = ±12; Late-stage Gsdmd+/+xP301S: n = ±20, Gsdmd−/−xP301S: n = ±15. No significance by unpaired t-test of age-matched groups.

    Article Snippet: Slices were treated with 1 μM of a NLRP3 small molecule inhibitor [Compound 1; example 49 of WO2020234715A1 (Novartis AG)].

    Techniques: Immunohistochemistry

    FIGURE 7 No impact of Gsdmd and Nlrp3 deficiency on plasma IL-18 levels in P301S mice. (A) Mesoscale measurement of pro-inflammatory IL-18 levels in plasma of P301S mice. No significant difference between Nlrp3 knockout mice vs. Nlrp3 WT mice in early and late-stage P301S mice. Early stage Nlrp3+/+xP301S: n = 18, Nlrp3−/−xP301S n = 26; Late-stage Nlrp3+/+xP301S: n = 16, Nlrp3−/−xP301S: n = 18. No significance by paired t-test of age- matched groups. (B) IL-18 concentrations were additionally quantified in plasma of early and late-stage Gsdmd−/−xP301S vs. Gsdmd+/+xP301S, demonstrating no effect of GSDMD. WT: n = 15; Early stage Nlrp3+/+xP301S: n = 8, Nlrp3−/−xP301S: n = 21; Late-stage Nlrp3+/+xP301S: n = 26, Nlrp3−/−xP301S: n = 19. No significance by paired t-test of age-matched groups.

    Journal: Frontiers in aging neuroscience

    Article Title: NLRP3 inflammasome activation and pyroptosis are dispensable for tau pathology.

    doi: 10.3389/fnagi.2024.1459134

    Figure Lengend Snippet: FIGURE 7 No impact of Gsdmd and Nlrp3 deficiency on plasma IL-18 levels in P301S mice. (A) Mesoscale measurement of pro-inflammatory IL-18 levels in plasma of P301S mice. No significant difference between Nlrp3 knockout mice vs. Nlrp3 WT mice in early and late-stage P301S mice. Early stage Nlrp3+/+xP301S: n = 18, Nlrp3−/−xP301S n = 26; Late-stage Nlrp3+/+xP301S: n = 16, Nlrp3−/−xP301S: n = 18. No significance by paired t-test of age- matched groups. (B) IL-18 concentrations were additionally quantified in plasma of early and late-stage Gsdmd−/−xP301S vs. Gsdmd+/+xP301S, demonstrating no effect of GSDMD. WT: n = 15; Early stage Nlrp3+/+xP301S: n = 8, Nlrp3−/−xP301S: n = 21; Late-stage Nlrp3+/+xP301S: n = 26, Nlrp3−/−xP301S: n = 19. No significance by paired t-test of age-matched groups.

    Article Snippet: Slices were treated with 1 μM of a NLRP3 small molecule inhibitor [Compound 1; example 49 of WO2020234715A1 (Novartis AG)].

    Techniques: Clinical Proteomics, Knock-Out

    NLRP3 inflammasome-targeted therapeutics in development.

    Journal: Frontiers in Immunology

    Article Title: Targeting the NLRP3 Inflammasome in Severe COVID-19

    doi: 10.3389/fimmu.2020.01518

    Figure Lengend Snippet: NLRP3 inflammasome-targeted therapeutics in development.

    Article Snippet: , N/A , NodThera , Small-molecule NLRP3 inhibitors expected to begin clinical studies this year , ( ) .

    Techniques: Recombinant, Binding Assay

    The NLRP3 inflammasome mediates lung inflammation in SARS-CoV-2 infection. SARS-CoV-2 is inhaled into the airway and mediates activation of the P2RX7 receptor by release of extracellular ATP. P2RX7 signaling can lead to NLRP3 activation through direct or indirect activation in activated macrophages. Activation of the NLRP3 inflammasome drives the secretion of IL-1β and IL-18 which can result in pyroptosis (programmed cell death). Activation of immune cell subsets, largely through activated macrophages, results in a cascade of massive inflammatory cytokine activation including IL-6, TNF-α, IL-8, IL-10, IL-1RA, and CXCL10 that lead to acute lung injury with acute respiratory distress syndrome, systemic inflammatory response syndrome (SIRS), shock and multiorgan dysfunction, and coagulopathy.

    Journal: Frontiers in Immunology

    Article Title: Targeting the NLRP3 Inflammasome in Severe COVID-19

    doi: 10.3389/fimmu.2020.01518

    Figure Lengend Snippet: The NLRP3 inflammasome mediates lung inflammation in SARS-CoV-2 infection. SARS-CoV-2 is inhaled into the airway and mediates activation of the P2RX7 receptor by release of extracellular ATP. P2RX7 signaling can lead to NLRP3 activation through direct or indirect activation in activated macrophages. Activation of the NLRP3 inflammasome drives the secretion of IL-1β and IL-18 which can result in pyroptosis (programmed cell death). Activation of immune cell subsets, largely through activated macrophages, results in a cascade of massive inflammatory cytokine activation including IL-6, TNF-α, IL-8, IL-10, IL-1RA, and CXCL10 that lead to acute lung injury with acute respiratory distress syndrome, systemic inflammatory response syndrome (SIRS), shock and multiorgan dysfunction, and coagulopathy.

    Article Snippet: , N/A , NodThera , Small-molecule NLRP3 inhibitors expected to begin clinical studies this year , ( ) .

    Techniques: Infection, Activation Assay

    NLRP3 inflammasome-targeted therapeutics in development.

    Journal: Frontiers in Immunology

    Article Title: Targeting the NLRP3 Inflammasome in Severe COVID-19

    doi: 10.3389/fimmu.2020.01518

    Figure Lengend Snippet: NLRP3 inflammasome-targeted therapeutics in development.

    Article Snippet: , Inzomelid (also Somalix) , Inflazome , Small-molecule NLRP3 inhibitors , ( , ) .

    Techniques: Recombinant, Binding Assay

    The NLRP3 inflammasome mediates lung inflammation in SARS-CoV-2 infection. SARS-CoV-2 is inhaled into the airway and mediates activation of the P2RX7 receptor by release of extracellular ATP. P2RX7 signaling can lead to NLRP3 activation through direct or indirect activation in activated macrophages. Activation of the NLRP3 inflammasome drives the secretion of IL-1β and IL-18 which can result in pyroptosis (programmed cell death). Activation of immune cell subsets, largely through activated macrophages, results in a cascade of massive inflammatory cytokine activation including IL-6, TNF-α, IL-8, IL-10, IL-1RA, and CXCL10 that lead to acute lung injury with acute respiratory distress syndrome, systemic inflammatory response syndrome (SIRS), shock and multiorgan dysfunction, and coagulopathy.

    Journal: Frontiers in Immunology

    Article Title: Targeting the NLRP3 Inflammasome in Severe COVID-19

    doi: 10.3389/fimmu.2020.01518

    Figure Lengend Snippet: The NLRP3 inflammasome mediates lung inflammation in SARS-CoV-2 infection. SARS-CoV-2 is inhaled into the airway and mediates activation of the P2RX7 receptor by release of extracellular ATP. P2RX7 signaling can lead to NLRP3 activation through direct or indirect activation in activated macrophages. Activation of the NLRP3 inflammasome drives the secretion of IL-1β and IL-18 which can result in pyroptosis (programmed cell death). Activation of immune cell subsets, largely through activated macrophages, results in a cascade of massive inflammatory cytokine activation including IL-6, TNF-α, IL-8, IL-10, IL-1RA, and CXCL10 that lead to acute lung injury with acute respiratory distress syndrome, systemic inflammatory response syndrome (SIRS), shock and multiorgan dysfunction, and coagulopathy.

    Article Snippet: , Inzomelid (also Somalix) , Inflazome , Small-molecule NLRP3 inhibitors , ( , ) .

    Techniques: Infection, Activation Assay